EurekAlert!3y
SCAI Stages of Cardiogenic Shock (IMAGE)
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert ...
MyChesCo on MSN1mon
Windtree Therapeutics Begins SEISMiC C Trial for Advanced Cardiogenic Shock
SCAI Stage C cardiogenic shock is characterized by significant organ hypoperfusion, necessitating the use of inotropic or ...
Zacks Small Cap Research on MSN1mon
WINT: Patient Enrollment in SEISMiC C Trial Starts, Patent Position Expands
The company’s lead indication area is cardiogenic shock (which is a severe form of heart failure) with istaroxime. Windtree ...
Nasdaq27d
Windtree Therapeutics reports Q3 EPS ($4.23) vs. ($15.47) last year
Looking forward, we plan to accelerate enrollments in the istaroxime SCAI Stage C cardiogenic shock study with a planned interim data read out in early Q2 2025 as well as providing guidance on our ...
Taiwan News26d
Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates
“Looking forward, we plan to accelerate enrollments in the istaroxime SCAI Stage C cardiogenic shock study with a planned interim data read out in early Q2 2025 as well as providing guidance on our ...